Big Pharma is pouring money into tech-devised treatments, but the verdict is out on whether they’ll actually work.

Parkinson drug development halted as Biogen and Denali stop BIIB122 after phase 2b trial failed to slow disease progression.

Early-stage drug development worldwide has nearly doubled over the past decade and shifted from a U.S.-dominated model to a dual hub centered in the United States and China, according to new research ...

The goal of this collaborative was to examine the contributing factors towards the failure of late-stage clinical product development and develop key considerations for stakeholders to improve the ...

Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...

Biogen and Denali’s Parkinson’s disease drug failed to significantly slow disease progression in a Phase 2b study, missing ...

May 21 (Reuters) - Biogen and Denali Therapeutics said on Thursday they will discontinue development of their Parkinson's ...

Proponents of price controls are wagering that savings on medicines will outweigh the lost benefits. The opposite is true.

Dec 11 (Reuters) - AnaptysBio (ANAB.O), opens new tab will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said ...

By Kamal Choudhury and Christy Santhosh May 18 (Reuters) - U.S. President Donald Trump's executive order to accelerate ...

The partnership will combine OpenBench’s discovery platform with Concept Life Sciences’ expertise in medicinal chemistry.

WASHINGTON — Early-stage drug development worldwide has nearly doubled over the past decade and shifted from a U.S.-dominated model to a dual hub centered in the United States and China, according to ...